EUVIMEDEUVIMED entdecken
Crossref

Clopidogrel Hyperresponsiveness and Hemorrhagic Complications Using On-Label Clopidogrel Dosing after Pipeline Embolization

Paige Morgan Nickelsen iD, Ron Neyens iD, Sami Al Kasab

Journal of Pharmacy Practice · 2025

DOI: 10.1177/08971900241273311 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy Practice, 2025. Verfasst von Paige Morgan Nickelsen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of California San Diego Health, San Diego, CA, USA. Hauptthemen laut MEDLINE: Clopidogrel, Embolization, Therapeutic, Platelet Aggregation Inhibitors. Die Arbeit nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Clopidogrel hyperresponsiveness is a timely topic, with wide ranging reports of hemorrhagic complications, using various clopidogrel dosing strategies following neuroendovascular procedures. This study serves to investigate hemorrhagic complications using standard clopidogrel doses and timing of these complications in relation to the procedure. Materials and Methods: Retrospective cohort of consecutive adult patients undergoing flow diversion with Pipeline Embolization Device (PED) at an academic medical center, receiving on-label clopidogrel doses. Patients with clopidogrel hyperresponsiveness (VerifyNow TM P2Y12 reaction unit (PRU) ≤ 70) were compared to those who were normoresponsive. The primary outcome is the rate of hemorrhagic complications between groups.

Results

Of 148 included patients, 54 (36.5%) were identified as clopidogrel hyperresponsive (PRU ≤ 70) and 94 (63.5%) as clopidogrel normoresponsive (PRU 71 – 194). There were no hemorrhagic complications observed in patients who were clopidogrel hyperresponsive, with 5 occurring in patients who were normoresponsive ( P = 0.09). Three (60%) of the hemorrhages were intracranial with most occurring intra-procedure or within the first week of the procedure. Age > 60 years was the only candidate predictor for hemorrhagic complications ( P = 0.004).

Conclusion

Our findings are contradictory, with lower hemorrhagic complications in clopidogrel hyperresponders than prior literature, and most occurring intra-op or in the immediate acute post-op phase.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClopidogrelEmbolization, TherapeuticPlatelet Aggregation InhibitorsHumansMaleMiddle AgedFemaleRetrospective StudiesAgedAdultCohort StudiesHemorrhageTiclopidine

Stichwörter der Autor:innen

clopidogrelhyper responsivepipeline embolization deviceplatelet function testing

Substanzen

ClopidogrelPlatelet Aggregation InhibitorsTiclopidine

Autor:innen und Institutionen

  • Department of Pharmacy, University of California San Diego Health, San Diego, CA, USA.
  • Department of Pharmacy, Medical University of South Carolina, San Diego, CA, USA.
  • College of Pharmacy, Medical University of South Carolina, San Diego, CA, USA.
  • Department of Neurosurgery, Medical University of South Carolina, San Diego, CA, USA.
  • Department of Neurology, Medical University of South Carolina, San Diego, CA, USA.

ORCID-Profile: Paige Morgan Nickelsen, Ron Neyens

Zitieren

APA

Nickelsen, P. M., Neyens, R., & Al Kasab, S. (2025). Clopidogrel Hyperresponsiveness and Hemorrhagic Complications Using On-Label Clopidogrel Dosing after Pipeline Embolization. Journal of Pharmacy Practice. https://doi.org/10.1177/08971900241273311

Vancouver

Nickelsen PM, Neyens R, Al Kasab S. Clopidogrel Hyperresponsiveness and Hemorrhagic Complications Using On-Label Clopidogrel Dosing after Pipeline Embolization. Journal of Pharmacy Practice. 2025. doi:10.1177/08971900241273311

BibTeX
@article{Nickelsen2025,
  author = {Nickelsen, Paige Morgan and Neyens, Ron and Al Kasab, Sami},
  title = {Clopidogrel Hyperresponsiveness and Hemorrhagic Complications Using On-Label Clopidogrel Dosing after Pipeline Embolization},
  journal = {Journal of Pharmacy Practice},
  year = {2025},
  doi = {10.1177/08971900241273311}
}
Kostenlos starten →